BTIG Says Kite Pharma's (KITE) ZUMA-1 Data Doesn't Alter Broader Picture; Affirms at 'Neutral'

September 27, 2016 12:13 PM EDT
Get Alerts KITE Hot Sheet
Price: $46.61 +3.42%

Rating Summary:
    15 Buy, 2 Hold, 0 Sell

Rating Trend: Down Down

Today's Overall Ratings:
    Up: 20 | Down: 36 | New: 11
Trade KITE Now!
Join SI Premium – FREE

Get instant alerts when news breaks on your stocks. Claim your 2-week free trial to StreetInsider Premium here.

BTIG affirmed its Neutral rating on Kite Pharma (Nasdaq: KITE) amid ZUMA-1 study results released Monday night.

Analyst Dane Leone commented, We think that the 3-month Complete Response rate of ~33% for the DLBCL cohort is within the 30 – 40% range expected by investors, and the 2 patient deaths as a result of Cytokine Release Syndrome may create some investor concern regarding FDA approvability. Overall, the 3-month results from the ZUMA-1 study does not alter our expectations relative to Juno (Nasdaq: JUNO) or Novartis (NYSE: NVS).

For an analyst ratings summary and ratings history on Kite Pharma click here. For more ratings news on Kite Pharma click here..



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In






Related Categories

Analyst Comments, FDA

Related Entities

BTIG

Add Your Comment